MFE-280from AcceGen |
|
ABC-TC5551 | 1 vial: Ask for price | |
Description: MFE-280 was derived from a recurrent, poorly differentiated endometrial carcinoma from a 78 year old patient. Initially, cells were grown as aggregates in suspension for one year, after which they were transferred to monolayer culture. The karyotype analysis revealed near-diploidy with a complex heterogeneous aberration pattern. MFE-280 were found to be positive for cytokines 7, 8, 18 and 19 as well as for vimentin. In addition, the cells express the placental protein 14, PP14. They have been shown to be tumorigenic in nude mice. |
|
MFE-296from AcceGen |
|
ABC-TC1325 | 1 vial: Ask for price | |
Description: MFE-296 was obtained from a moderately differentiated human endometrial adenocarcinoma. The cells were shown to express functionally intact androgen receptors. Proliferation was inhibted by progestin R5020 and dihydrotestosterone (DHT), the latter one being antagonised by the antiandrogen Casodex. MFE-296 express vimentin and the cytokeratins 7, 8, 18 and 19. Karyotype analysis revealed near tetraploidy for most cells. Further more, the cells have been shown to be tumorigenic in nude mice. |
|
MFE-2 antibodyfrom SAB |
|
23021 | 100ul: 479.00 EUR | |
MFE-2 antibodyfrom SAB |
|
23021-100ul | 100ul: 468.00 EUR | |
Mfe Ifrom GeneOn |
|
E296 | 5000 units: 410.40 EUR | |
m-Fexofenadine Ethyl Esterfrom Toronto Research Chemicals |
|
E917950 | 250mg: 800.00 EUR |